An IIFL report quotes the management of Strides Shasun as saying that pharmaceutical benefits scheme price cuts have bottomed out. In an interview to CNBC-TV18, Shashank Sinha, MD of the company spoke about the same and gave his outlook for the future.
Sinha said that we are hoping to launch 12-15 new products in next one year.
He further said that under the new Generic Drug User Fee Amendments (GDUFA) regime, abbreviated new drug applications (ANDAs) are approved within a year.
Talking about business, he said we have been investing heavily in the business, especially research and development (R&D).
We are targeting 30-35 product launches on an annual basis in Australia, he added.For entire interview, watch accompanying video.